Clinicians & Researchers

We are working hard to deliver better treatments to your patients.

We are developing new medicines to treat life-threatening, rare central nervous system (CNS) disorders and have built a robust pipeline focused on acute and orphan CNS indications. With clinically validated targets and accelerated development timelines, we are committed to delivering important new medicines to patients rapidly.

Clinical Trials

Discover treatments in development for your patients.

When it comes to living with central nervous system (CNS) disorders, we have one important goal: to make life better for your patients and their families. Our team is working every day to discover, develop and deliver important new medicines to treat these life-threatening, rare diseases.

Which trial is right for my patient?

Upcoming Medical Meetings

Discover SAGE at upcoming medical meetings.

Please Check Back Soon

Reference Library

Discover our research.

The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors.
Paul, et.al, J Neurosci. 2013 Oct 30;33(44):17290-300. doi: 10.1523/JNEUROSCI.2619-13.2013.

Neuroactive steroids for the treatment of status epilepticus.
Rogawski, et. al., Epilepsia. 2013 Sep;54 Suppl 6:93-8. doi: 10.1111/epi.12289.

Different oxysterols have opposing actions at N-methyl-D-aspartate receptors.
Linsenbardt, et. al., Neuropharmacology. 2014 Oct;85:232-42. doi: 10.1016/j.neuropharm.2014.05.027. Epub 2014 May 27.